Realizing individualized medicine: The road to translating proteomics from the laboratory to the clinic

Personalized Medicine

Volumn 8, Issue 1, 2011, Pages 45-57

  Rahbar, Amir ^a   Rivers, Robert ^a   Boja, Emily ^a   Kinsinger, Christopher ^a   Mesri, Mehdi ^a   Hiltke, Tara ^a   Rodriguez, Henry ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

biomarkers; diagnostics; enzyme linked immunosorbent assay; individualized medicine; mass spectrometry; proteins; proteomics

Indexed keywords

ABACAVIR; ATORVASTATIN; BIOLOGICAL MARKER; BUSULFAN; CARBAMAZEPINE; CETUXIMAB; DASATINIB; ERLOTINIB; IMATINIB; IRINOTECAN; MARAVIROC; PANITUMUMAB; TRASTUZUMAB; WARFARIN;

BIPOLAR DISORDER; BREAST CANCER; CARDIOVASCULAR DISEASE; COLON CANCER; COLORECTAL CANCER; DIAGNOSTIC TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; EPILEPSY; GENE SEQUENCE; GENOMICS; HEAD AND NECK CANCER; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LEUKEMIA; LUNG CANCER; MASS SPECTROMETRY; MOLECULAR DIAGNOSIS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEOMICS; REVIEW; STOMACH CANCER; TECHNOLOGY;

EID: 78650604145     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.10.76     Document Type: Review

References (90)

1. Venter JC, Adams MD, Myers EW et al.: The sequence of the human genome. Science 291(5507), 1304-1351 (2001).
2. Linkov F, Lisovich A, Yurkovetsky Z et al.: Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profling. Cancer Epidemiol. Biomarkers Prev. 16(1), 102-107 (2007).
3. Li Y, St John MA, Zhou X et al.: Salivary transcriptome diagnostics for oral cancer detection. Clin. Cancer Res. 10(24), 8442-8450 (2004).
4. Li Y, Zhou X, St John MA, Wong DT: RNA profling of cell-free saliva using microarray technology. J. Dent. Res. 83(3), 199-203 (2004).
5. Johansson B, Fioretos T, Mitelman F: Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 107(2), 76-94 (2002).
6. Motsinger-Reif AA, Jorgenson E, Relling MV et al.: Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet. Genomics (2010) (Epub ahead of print).
7. Ingelman-Sundberg M, Sim SC: Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system. Biochem. Biophys. Res. Commun. 396(1), 90-94 (2010).
8. Cameron D, Casey M, Press M et al.: A Phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated effcacy and biomarker analyses. Breast Cancer Res. Treat. 112(3), 533-543 (2008).
9. Rosell R, Ichinose Y, Taron M et al.: Mutations in the tyrosine kinase domain of the EGFR gene associated with geftinib response in non-small-cell lung cancer. Lung Cancer 50(1), 25-33 (2005).
10. Reddy GK: Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer. Clin. Lung Cancer 7(3), 163-165 (2005).
11. Silvestri GA, Rivera MP: Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. Chest 128(6), 3975-3984 (2005).
12. Byrne BJ, Garst J: Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer. Curr. Oncol. Rep. 7(4), 241-247 (2005).
13. Jabbour E, Cortes J, Kantarjian H: Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias. Expert Opin. Investig Drugs 16(5), 679-687 (2007).
14. Melo JV, Hughes TP, Apperley JF: Chronic myeloid leukemia. Hematology Am. Soc Hematol. Educ Program, 132-152 (2003).
15. Anderson NL: The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin. Chem. 56(2), 177-185 (2010).
16. Stoevesandt O, Taussig MJ: Affnity reagent resources for human proteome detection: initiatives and perspectives. Proteomics 7(16), 2738-2750 (2007).
17. Meani F, Pecorelli S, Liotta L, Petricoin EF: Clinical application of proteomics in ovarian cancer prevention and treatment. Mol. Diagn. Ther. 13(5), 297-311 (2009).
18. Ruiz-Romero C, Blanco FJ: Proteomics role in the search for improved diagnosis, prognosis and treatment of osteoarthritis. Osteoarthritis Cartilage 18(4), 500-509 (2010).
19. Ulrich-Merzenich G, Zeitler H, Jobst D et al.: Application of the '-Omic-' technologies in phytomedicine. Phytomedicine 14(1), 70-82 (2007).
20. Hawkins RD, Hon GC, Ren B: Next-generation genomics: an integrative approach. Nat. Rev. Genet. 11(7), 476-486 (2010).
21. Graves PR, Haystead TA: Molecular biologist's guide to proteomics. Microbiol. Mol. Biol. Rev. 66(1), 39-63; table of contents (2002).
22. Deutzmann R: Structural characterization of proteins and peptides. Methods Mol. Med. 94, 269-297 (2004).
23. Kramer MF, Coen DM: Enzymatic amplifcation of DNA by PCR: standard procedures and optimization. Curr. Protoc Immunol. Chapter 10, Unit 10.20 (2001).
24. Anderson NL, Anderson NG: The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell Proteomics 1(11), 845-867 (2002).
25. Bakalarski CE, Elias JE, Villen J et al.: The impact of peptide abundance and dynamic range on stable-isotope-based quantitative proteomic analyses. J. Proteome Res. 7(11), 4756-4765 (2008).
26. Breitbart RE, Andreadis A, Nadal-Ginard B: Alternative splicing: a ubiquitous mechanism for the generation of multiple protein isoforms from single genes. Annu. Rev. Biochem. 56, 467-495 (1987).
27. Stein LD: Human genome: end of the beginning. Nature 431(7011), 915-916 (2004).
28. Uhlen M, Ponten F: Antibody-based proteomics for human tissue profling. Mol. Cell Proteomics 4(4), 384-393 (2005).
29. Mischak H, Apweiler R, Banks RE et al.: Clinical proteomics: a need to defne the feld and to begin to set adequate standards. Proteomics Clin. Appl. 1, 148-156 (2007).
30. Geho DH, Petricoin EF, Liotta LA, Araujo RP: Modeling of protein signaling networks in clinical proteomics. Cold Spring Harb. Symp. Quant. Biol. 70, 517-524 (2005).
31. Tripathi V, Nara S, Chaube SK et al.: Development of rapid and sensitive one-step direct enzyme linked immunosorbent assay for 17-ct-OH-progesterone in serum. J. Immunoassay Immunochem. 29(2), 117-127 (2008).
32. Saita T, Tokunaga A, Egoshi M, Tokushima H, Fujito H: Quantifcation of cibenzoline by enzyme-linked immunosorbent assay Yakugaku Zasshi 127(6), 1007-1012 (2007).
33. Welp A, Manz B, Peschke E: Development and validation of a high throughput direct radioimmunoassay for the quantitative determination of serum and plasma melatonin (N-acetyl-5-methoxytryptamine) in mice. J. Immunol. Methods 358(1-2), 1-8 (2010).
34. Tsai HY, Chan JR, Li YC, Cheng FC, Fuh CB: Determination of hepatitis B surface antigen using magnetic immunoassays in a thin channel. Biosens. Bioelectron. 25(12), 2701-2705 (2010).
35. Dunbar E, Yachnis AT: Glioma diagnosis: immunohistochemistry and beyond. Adv. Anat. Pathol. 17(3), 187-201 (2010).
36. Reuter VE, Tickoo SK: Differential diagnosis of renal tumours with clear cell histology. Pathology 42(4), 374-383 (2010).
37. Tholouli E, Sweeney E, Barrow E et al.: Quantum dots light up pathology. J. Pathol. 216(3), 275-285 (2008).
38. Xiao Y, Gao X: Use of IgY antibodies and semiconductor nanocrystal detection in cancer biomarker quantitation. Biomark. Med. 4(2), 227-239 (2010).
39. Cregger M, Berger AJ, Rimm DL: Immunohistochemistry and quantitative ana lysis of protein expression. Arch. Pathol. Lab. Med. 130(7), 1026-1030 (2006).
40. Lim CT, Zhang Y: Bead-based microfuidic immunoassays: the next generation. Biosens. Bioelectron. 22(7), 1197-1204 (2007).
41. Idikio HA: Immunohistochemistry in diagnostic surgical pathology: contributions of protein life-cycle, use of evidence-based methods and data normalization on interpretation of immunohistochemical stains. Int. J. Clin. Exp. Pathol. 3(2), 169-176 (2009).
42. Schwarz E, Izmailov R, Spain M et al.: Validation of a blood-based laboratory test to aid in the confrmation of a diagnosis of schizophrenia. Biomark Insights 5, 39-47 (2010).
43. Rifai N, Gillette MA, Carr SA: Protein biomarker discovery and validation: the long and uncertain path to clinical utility Nat. Biotechnol. 24(8), 971-983 (2006).
44. de Snoo F, Bender R, Glas A, Rutgers E: Gene expression profling: decoding breast cancer. Surg Oncol. 18(4), 366-378 (2009).
45. Ragoussis J, Elvidge G: Affymetrix GeneChip system: moving from research to the clinic. Expert Rev. Mol. Diagn. 6(2), 145-152 (2006).
46. Stoevesandt O, Taussig MJ, He M: Protein microarrays: high-throughput tools for proteomics. Expert Rev. Proteomics 6(2), 145-157 (2009).
47. Voshol H, Ehrat M, Traenkle J, Bertrand E, van Oostrum J: Antibody-based proteomics: ana lysis of signaling networks using reverse protein arrays. FEBS J. 276(23), 6871-6879 (2009).
48. Zong Y, Zhang S, Chen HT, Shi Y: Forward-phase and reverse-phase protein microarray Methods Mol. Biol. 381, 363-374 (2007).
49. Lorenz P, Kreutzer M, Zerweck J, Schutkowski M, Thiesen HJ: Probing the epitope signatures of IgG antibodies in human serum from patients with autoimmune disease. Methods Mol. Biol. 524, 247-258 (2009).
50. Canas B, Lopez-Ferrer D, Ramos-Fernandez A, Camafeita E, Calvo E: Mass spectrometry technologies for proteomics. Brief Funct. Genomic Proteomic 4(4), 295-320 (2006).
51. Han X, Aslanian A, Yates JR 3rd: Mass spectrometry for proteomics. Curr. Opin. Chem. Biol. 12(5), 483-490 (2008).
52. Domon B, Aebersold R: Mass spectrometry and protein ana lysis. Science 312 (5771), 212-217 (2006)
53. Stults JT Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS). Curr. Opin. Struct. Biol. 5(5), 691-698 (1995).
54. Caprioli RM, Farmer TB, Gile J: Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. Anal. Chem. 69(23), 4751-4760 (1997).
55. Franck J, Arafah K, Elayed M et al.: MALDI imaging mass spectrometry: state of the art technology in clinical proteomics. Mol. Cell Proteomics 8(9), 2023-2033 (2009).
56. Francese S, Dani FR, Traldi P et al.: MALDI mass spectrometry imaging, from its origins up to today: the state of the art. Comb. Chem. High Throughput Screen 12(2), 156-174 (2009).
57. Walch A, Rauser S, Deininger SO, Hofer H: MALDI imaging mass spectrometry for direct tissue ana lysis: a new frontier for molecular histology. Histochem. Cell Biol. 130(3), 421-434 (2008).
58. Kuwata H, Yip TT, Yip CL, Tomita M, Hutchens TW: Bactericidal domain of lactoferrin: detection, quantitation, and characterization of lactoferricin in serum by SELDI affnity mass spectrometry. Biochem. Biophys. Res. Commun. 245(3), 764-773 (1998).
59. Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM: Electrospray ionization for mass spectrometry of large biomolecules. Science 246(4926), 64-71 (1989).
60. Ahmed FE: Utility of mass spectrometry for proteome ana lysis: part I. Conceptual and experimental approaches. Expert Rev. Proteomics 5(6), 841-864 (2008).
61. Anderson L, Hunter CL: Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell Proteomics 5(4), 573-588 (2006).
62. Kitteringham NR, Jenkins RE, Lane CS, Elliott VL, Park BK: Multiple reaction monitoring for quantitative biomarker ana lysis in proteomics and metabolomics. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877(13), 1229-1239 (2009).
63. Kim K, Kim Y: Preparing multiple-reaction monitoring for quantitative clinical proteomics. Expert Rev. Proteomics 6(3), 225-229 (2009).
64. Makawita S, Diamandis EP: The bottleneck in the cancer biomarker pipeline and protein quantifcation through mass spectrometry-based approaches: current strategies for candidate verifcation. Clin. Chem. 56(2), 212-222 (2010).
65. Reid JD, Holmes DT, Mason DR, Shah B, Borchers CH: Towards the development of an immuno MALDI (iMALDI) mass spectrometry assay for the diagnosis of hypertension. J. Am. Soc Mass Spectrom. 21(10), 1680-1686 (2010).
66. Anderson NL, Anderson NG, Haines LR et al.: Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by AntiPeptide Antibodies (SISCAPA). J. Proteome Res. 3(2), 235-244 (2004).
67. Kuhn E, Addona T, Keshishian H et al.: Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffnity enrichment and targeted mass spectrometry. Clin. Chem. 55(6), 1108-1117 (2009).
68. Tuli L, Ressom HW: LC-MS Based detection of differential protein expression. J. Proteomics Bioinform. 2, 416-438 (2009).
69. Nagy K, Takats Z, Pollreisz F, Szabo T, Vekey K: Direct tandem mass spectrometric ana lysis of amino acids in dried blood spots without chemical derivatization for neonatal screening. Rapid Commun. Mass Spectrom. 17(9), 983-990 (2003).
70. Li W, Tse FL: Dried blood spot sampling in combination with LC-MS/MS for quantitative ana lysis of small molecules. Biomed. Chromatogr. 24(1), 49-65 (2010).
71. Ghoshal AK, Guo T, Soukhova N, Soldin SJ: Rapid measurement of plasma acylcarnitines by liquid chromatography-tandem mass spectrometry without derivatization. Clin. Chim. Acta 358(1-2), 104-112 (2005).
72. Lindner M, Hoffmann GF, Matern D: Newborn screening for disorders of fatty-acid oxidation: experience and recommendations from an expert meeting. J. Inherit. Metab. Dis. 33(5), 521-526 (2010).
73. Meany DL, Sokoll LJ, Chan DW: Early detection of cancer: immunoassays for plasma tumor markers. Expert Opin. Med. Diagn. 3(6), 597-605 (2009).
74. Lippi G, Salvagno GL, Montagnana M, Guidi GC: Reliability of the thrombin-generation assay in frozen-thawed platelet-rich plasma. Clin. Chem. 52(9), 1827-1828 (2006).
75. Apweiler R, Aslanidis C, Deufel T et al.: Approaching clinical proteomics: current state and future felds of application in fuid proteomics. Clin. Chem. Lab. Med. 47(6), 724-744 (2009).
76. Apweiler R, Aslanidis C, Deufel T et al.: Approaching clinical proteomics: current state and future felds of application in cellular proteomics. Cytometry A 75(10), 816-832 (2009).
77. Vaught JB, Caboux E, Hainaut P: International efforts to develop biospecimen best practices. Cancer Epidemiol. Biomarkers Prev. 19(4), 912-915 (2010).
78. Lescuyer P, Farina A, Hochstrasser DF: Proteomics in clinical chemistry: will it be long? Trends Biotechnol. 28(5), 225-229 (2010).
79. Addona TA, Abbatiello SE, Schilling B et al.: Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat. Biotechnol. 27(7), 633-641 (2009).
80. Rudnick PA, Clauser KR, Kilpatrick LE et al.: Performance metrics for liquid chromatography-tandem mass spectrometry systems in proteomics analyses. Mol. Cell Proteomics 9(2), 225-241 (2010).
81. Paulovich AG, Billheimer D, Ham AJ et al.: Interlaboratory study characterizing a yeast performance standard for benchmarking LC-MS platform performance. Mol. Cell Proteomics 9(2), 242-254 (2010).
82. Hoofnagle AN: Quantitative clinical proteomics by liquid chromatography-tandem mass spectrometry: assessing the platform. Clin. Chem. 56(2), 161-164 (2010).
83. Pedrioli PG, Eng JK, Hubley R et al.: A common open representation of mass spectrometry data and its application to proteomics research. Nat. Biotechnol. 22(11), 1459-1466 (2004).
84. Orchard S, Hermjakob H, Taylor CF et al.: Further steps in standardisation. report of the second annual proteomics standards initiative spring workshop (Siena, Italy 17-20th April 2005). Proteomics 5(14), 3552-3555 (2005).
85. Deutsch E: mzML: a single, unifying data format for mass spectrometer output. Proteomics 8(14), 2776-2777 (2008).
86. Rodriguez H, Snyder M, Uhlen M et al.: Recommendations from the 2008 International Summit on Proteomics Data Release and Sharing Policy: the Amsterdam principles. J. Proteome Res. 8(7), 3689-3692 (2009).
87. Cottingham K: MCP ups the ante by mandating raw-data deposition. J. Proteome Res. 8(11), 4887-4888 (2009).
88. Gerszten RE, Carr SA, Sabatine M: Integration of proteomic-based tools for improved biomarkers of myocardial injury Clin. Chem. 56(2), 194-201 (2010).
89. Paulovich AG, Whiteaker JR, Hoofnagle AN, Wang P: The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline. Proteomics Clin. Appl. 2, 1386-1402 (2008).
90. Polanski M, Anderson NL: A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights 1, 1-48 (2007).